Cargando…
Evidence-based hyponatremia management in liver disease
Hyponatremia is primarily a water balance disorder associated with high morbidity and mortality. The pathophysiological mechanisms behind hyponatremia are multifactorial, and diagnosing and treating this disorder remains challenging. In this review, the classification, pathogenesis, and step-by-step...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577348/ https://www.ncbi.nlm.nih.gov/pubmed/37280091 http://dx.doi.org/10.3350/cmh.2023.0090 |
_version_ | 1785121307274248192 |
---|---|
author | Ryu, Ji Young Baek, Seon Ha Kim, Sejoong |
author_facet | Ryu, Ji Young Baek, Seon Ha Kim, Sejoong |
author_sort | Ryu, Ji Young |
collection | PubMed |
description | Hyponatremia is primarily a water balance disorder associated with high morbidity and mortality. The pathophysiological mechanisms behind hyponatremia are multifactorial, and diagnosing and treating this disorder remains challenging. In this review, the classification, pathogenesis, and step-by-step management approaches for hyponatremia in patients with liver disease are described based on recent evidence. We summarize the five sequential steps of the traditional diagnostic approach: 1) confirm true hypotonic hyponatremia, 2) assess the severity of hyponatremia symptoms, 3) measure urine osmolality, 4) classify hyponatremia based on the urine sodium concentration and extracellular fluid status, and 5) rule out any coexisting endocrine disorder and renal failure. Distinct treatment strategies for hyponatremia in liver disease should be applied according to the symptoms, duration, and etiology of disease. Symptomatic hyponatremia requires immediate correction with 3% saline. Asymptomatic chronic hyponatremia in liver disease is prevalent and treatment plans should be individualized based on diagnosis. Treatment options for correcting hyponatremia in advanced liver disease may include water restriction; hypokalemia correction; and administration of vasopressin antagonists, albumin, and 3% saline. Safety concerns for patients with liver disease include a higher risk of osmotic demyelination syndrome. |
format | Online Article Text |
id | pubmed-10577348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Korean Association for the Study of the Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-105773482023-10-17 Evidence-based hyponatremia management in liver disease Ryu, Ji Young Baek, Seon Ha Kim, Sejoong Clin Mol Hepatol Review Hyponatremia is primarily a water balance disorder associated with high morbidity and mortality. The pathophysiological mechanisms behind hyponatremia are multifactorial, and diagnosing and treating this disorder remains challenging. In this review, the classification, pathogenesis, and step-by-step management approaches for hyponatremia in patients with liver disease are described based on recent evidence. We summarize the five sequential steps of the traditional diagnostic approach: 1) confirm true hypotonic hyponatremia, 2) assess the severity of hyponatremia symptoms, 3) measure urine osmolality, 4) classify hyponatremia based on the urine sodium concentration and extracellular fluid status, and 5) rule out any coexisting endocrine disorder and renal failure. Distinct treatment strategies for hyponatremia in liver disease should be applied according to the symptoms, duration, and etiology of disease. Symptomatic hyponatremia requires immediate correction with 3% saline. Asymptomatic chronic hyponatremia in liver disease is prevalent and treatment plans should be individualized based on diagnosis. Treatment options for correcting hyponatremia in advanced liver disease may include water restriction; hypokalemia correction; and administration of vasopressin antagonists, albumin, and 3% saline. Safety concerns for patients with liver disease include a higher risk of osmotic demyelination syndrome. The Korean Association for the Study of the Liver 2023-10 2023-06-05 /pmc/articles/PMC10577348/ /pubmed/37280091 http://dx.doi.org/10.3350/cmh.2023.0090 Text en Copyright © 2023 by The Korean Association for the Study of the Liver https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Ryu, Ji Young Baek, Seon Ha Kim, Sejoong Evidence-based hyponatremia management in liver disease |
title | Evidence-based hyponatremia management in liver disease |
title_full | Evidence-based hyponatremia management in liver disease |
title_fullStr | Evidence-based hyponatremia management in liver disease |
title_full_unstemmed | Evidence-based hyponatremia management in liver disease |
title_short | Evidence-based hyponatremia management in liver disease |
title_sort | evidence-based hyponatremia management in liver disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577348/ https://www.ncbi.nlm.nih.gov/pubmed/37280091 http://dx.doi.org/10.3350/cmh.2023.0090 |
work_keys_str_mv | AT ryujiyoung evidencebasedhyponatremiamanagementinliverdisease AT baekseonha evidencebasedhyponatremiamanagementinliverdisease AT kimsejoong evidencebasedhyponatremiamanagementinliverdisease |